A Clinical Trial of MK-1167 in Healthy Adults (MK-1167-010)

Merck Sharp & Dohme (MSD)

Status and phase: Enrolling; Phase 1

Conditions: Healthy

Treatments: Drug: Placebo; Drug: MK-1167

Study type: Interventional

Funder types: Industry

Identifiers

NCT07266818

1167-010

Details and patient eligibility

About

The goal of this trial is to learn about the safety of MK-1167 and if people tolerate it.

Enrollment: 30 estimated patients

Sex: All

Ages: 18 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

The key inclusion criteria but are not limited to the following:

• Is in good health
• Has a body mass index (BMI) ≥18 and ≤32 kg/m^2, inclusive

The key inclusion criteria but are not limited to the following:

• Has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological abnormalities or diseases
• Is a smoker and/or has used nicotine or nicotine-containing products (for example, nicotine patch and electronic cigarette) within the past 3 months

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

30 participants in 2 patient groups, including a placebo group

MK-1167

Experimental group

Description:

MK-1167 administered orally

Treatment:

Drug: MK-1167

Placebo

Placebo Comparator group

Description:

Placebo for MK-1167 administered orally

Treatment:

Drug: Placebo